HRP20140071T1 - Derivat piperidinila kao modulator aktivnosti receptora kemokina - Google Patents

Derivat piperidinila kao modulator aktivnosti receptora kemokina Download PDF

Info

Publication number
HRP20140071T1
HRP20140071T1 HRP20140071AT HRP20140071T HRP20140071T1 HR P20140071 T1 HRP20140071 T1 HR P20140071T1 HR P20140071A T HRP20140071A T HR P20140071AT HR P20140071 T HRP20140071 T HR P20140071T HR P20140071 T1 HRP20140071 T1 HR P20140071T1
Authority
HR
Croatia
Prior art keywords
active substances
acid
additional active
compound
inhibitors
Prior art date
Application number
HRP20140071AT
Other languages
English (en)
Croatian (hr)
Inventor
Joseph B. Santella
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of HRP20140071T1 publication Critical patent/HRP20140071T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HRP20140071AT 2008-06-25 2009-06-25 Derivat piperidinila kao modulator aktivnosti receptora kemokina HRP20140071T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7539408P 2008-06-25 2008-06-25
US12/490,477 US8299098B2 (en) 2008-06-25 2009-06-24 Piperidinyl derivative as a modulator of chemokine receptor activity
PCT/US2009/048564 WO2009158452A1 (en) 2008-06-25 2009-06-25 Piperidinyl derivative as a modulator of chemokine receptor activity

Publications (1)

Publication Number Publication Date
HRP20140071T1 true HRP20140071T1 (hr) 2014-02-14

Family

ID=41060069

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20140071AT HRP20140071T1 (hr) 2008-06-25 2009-06-25 Derivat piperidinila kao modulator aktivnosti receptora kemokina

Country Status (24)

Country Link
US (2) US8299098B2 (enExample)
EP (1) EP2323983B1 (enExample)
JP (1) JP5357965B2 (enExample)
KR (1) KR20110023865A (enExample)
CN (1) CN102076663B (enExample)
AU (1) AU2009262219B2 (enExample)
BR (1) BRPI0914539A2 (enExample)
CA (1) CA2729016A1 (enExample)
CL (1) CL2010001566A1 (enExample)
CO (1) CO6321247A2 (enExample)
CY (1) CY1114994T1 (enExample)
DK (1) DK2323983T3 (enExample)
EA (1) EA021224B1 (enExample)
ES (1) ES2447740T3 (enExample)
HR (1) HRP20140071T1 (enExample)
IL (1) IL209832A (enExample)
MX (1) MX2010013664A (enExample)
NZ (1) NZ589909A (enExample)
PE (1) PE20110103A1 (enExample)
PL (1) PL2323983T3 (enExample)
PT (1) PT2323983E (enExample)
SI (1) SI2323983T1 (enExample)
TW (1) TWI433838B (enExample)
WO (1) WO2009158452A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433838B (zh) * 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
US8410139B2 (en) * 2009-10-07 2013-04-02 Bristol-Myers Squibb Company Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity
CN102648193A (zh) * 2009-10-07 2012-08-22 百时美施贵宝公司 作为趋化因子受体活性调节剂的螺环化合物
US8642622B2 (en) * 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity
US9095585B2 (en) 2011-07-21 2015-08-04 Bristol-Myers Squibb Company Bioavailable compositions of amorphous piperidinyl compounds
WO2013162984A1 (en) 2012-04-25 2013-10-31 Bristol-Myers Squibb Company Methods for identifying subjects with an increased likelihood of responding to ccr1 antagonist
US9257178B1 (en) * 2014-11-26 2016-02-09 Taiwan Semiconductor Manufacturing Company Limited Devices and methods for writing to a memory cell of a memory
EP3507830A4 (en) * 2016-08-31 2020-04-01 Micron Technology, Inc. MEMORY CELLS AND MEMORY MATRICES

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60163855A (ja) 1984-02-06 1985-08-26 Mitsubishi Chem Ind Ltd アルギニン誘導体および薬剤として許容され得るその酸付加塩
GB9104656D0 (en) 1991-03-05 1991-04-17 Zambeletti Spa L Pharmaceuticals
DE4243858A1 (de) 1992-12-23 1994-06-30 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5459151A (en) 1993-04-30 1995-10-17 American Home Products Corporation N-acyl substituted phenyl piperidines as bronchodilators and antiinflammatory agents
US5492920A (en) 1993-12-10 1996-02-20 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
US5777112A (en) 1994-06-13 1998-07-07 Merck & Co., Inc Piperazine compounds promote release of growth hormone
CA2226740A1 (en) 1995-07-13 1997-01-30 Mitsuyoshi Azuma Piperazine derivative and its uses
EP0944388A4 (en) 1996-04-03 2001-08-16 Merck & Co Inc INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
DE59711622D1 (de) 1996-09-10 2004-06-17 Boehringer Ingelheim Pharma Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
WO1998017625A1 (en) 1996-10-22 1998-04-30 Daiichi Pharmaceutical Co., Ltd. Novel remedies for infectious diseases
US5847148A (en) 1997-04-10 1998-12-08 Pharmacia & Upjohn Company Thiadiazole derivatives useful for the treatment of diseases related to connective tissue degradation
JPH1171350A (ja) * 1997-06-17 1999-03-16 Takeda Chem Ind Ltd ヒドロキシピペリジン化合物およびその剤
ZA987385B (en) 1997-08-19 2000-04-18 Lilly Co Eli Growth hormone secretagogues.
ZA987383B (en) 1997-08-19 2000-02-17 Lilly Co Eli Treatment of congestive heart failure with growth hormone secretagogues.
HUP0101419A3 (en) 1998-04-16 2002-08-28 Texas Biotechnology Corp Houst Compounds that inhibit the binding of integrins to their receptors and pharmaceutical compositions containing them
DE69925160T2 (de) 1998-12-17 2006-02-16 Wyeth Arylpiperidin- und aryl-1,2,5,6-tetrahydropyridinamid-derivate mit 5ht1a rezeptor aktivität
WO2000051609A1 (en) 1999-03-02 2000-09-08 Merck & Co., Inc. 3-alkyl substituted pyrrolidine modulators of chemokine receptor activity
US6391865B1 (en) 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
WO2000074679A1 (en) 1999-06-04 2000-12-14 Merck & Co., Inc. Substituted piperidines as melanocortin-4 receptor agonists
DE10041402A1 (de) 2000-08-23 2002-03-14 Morphochem Ag Neue Verbindungen, die Faktor Xa-Aktivität inhibieren
JP2001354657A (ja) 2000-06-09 2001-12-25 Sds Biotech:Kk 置換ピペラジン誘導体及び農園芸用殺菌剤
AU2001268607A1 (en) 2000-06-21 2002-01-02 Bristol-Myers Squibb Company Piperidine amides as modulators of chemokine receptor activity
DE10049699A1 (de) * 2000-10-07 2002-05-08 Bosch Gmbh Robert Anker für eine elektrische Maschine sowie Verfahren zu dessen Herstellung
JP2004523530A (ja) 2001-01-23 2004-08-05 イーライ・リリー・アンド・カンパニー メラノコルチン受容体アゴニストとしてのピペラジンおよびピペリジン誘導体
EP1363898A4 (en) 2001-03-02 2004-12-08 Bristol Myers Squibb Co COMPOUNDS SUITABLE AS MODULATORS OF MELANOCORTIN RECEPTORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6887924B2 (en) 2001-05-11 2005-05-03 Multisorb Technologies, Inc. Pressed adsorbent and method of fabrication thereof
DE10124041A1 (de) 2001-05-16 2002-11-21 Graffinity Pharm Design Gmbh Protease Inhibitoren
WO2003007949A1 (en) 2001-07-18 2003-01-30 Merck & Co., Inc. Bridged piperidine derivatives as melanocortin receptor agonists
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
MY141661A (en) 2001-09-06 2010-05-31 Schering Corp 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
DE60236458D1 (de) 2001-12-20 2010-07-01 Osi Pharm Inc Pyrrolopyrimidin a2b selektive antagonistische verbindungen, deren synthese und verwendung
KR20040068317A (ko) 2001-12-20 2004-07-30 오에스아이 파마슈티컬스, 인코포레이티드 피리미딘 ａ₂ｂ 선택성 길항 화합물, 그의 합성 방법 및용도
US7041681B2 (en) 2002-04-29 2006-05-09 Janssen Pharmaceutica N.V. Compounds as opioid receptor modulators
US20050256130A1 (en) 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
DK1531822T3 (da) 2002-06-12 2009-12-07 Chemocentryx Inc 1-aryl-4-substituerede piperazin derivater til anvendelse som CCR1 antagonister til behandlingen af inflammation og immunforstyrrelser
SE0202838D0 (sv) * 2002-09-24 2002-09-24 Astrazeneca Ab Chemical compounds
GB0224917D0 (en) 2002-10-25 2002-12-04 Novartis Ag Organic compounds
WO2004042351A2 (en) 2002-10-30 2004-05-21 Merck & Co., Inc. Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity
TWI291467B (en) 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor
CA2512886A1 (en) 2003-02-28 2004-09-10 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
US6846836B2 (en) 2003-04-18 2005-01-25 Bristol-Myers Squibb Company N-substituted phenylurea inhibitors of mitochondrial F1F0 ATP hydrolase
EP1633737A1 (en) 2003-06-13 2006-03-15 Schering Aktiengesellschaft Quinolyl amide derivatives as ccr-5 antagonists
GB0315203D0 (en) 2003-06-28 2003-08-06 Celltech R&D Ltd Chemical compounds
FR2862967B1 (fr) 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique
DE10358539A1 (de) 2003-12-15 2005-07-07 Merck Patent Gmbh Carbonsäureamidderivate
SE0400208D0 (sv) * 2004-02-02 2004-02-02 Astrazeneca Ab Chemical compounds
EP1722792A1 (de) 2004-03-03 2006-11-22 Boehringer Ingelheim International GmbH Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
GB0412468D0 (en) 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
AP2006003849A0 (en) 2004-06-28 2006-12-31 Incyte Corp 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors
AU2005259983B2 (en) 2004-06-28 2011-07-28 Incyte Corporation 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
US7723360B2 (en) 2004-08-06 2010-05-25 Boehringer Ingelheim International Gmbh Alkyl-and piperidine-substituted benzimidazole derivatives
US7566718B2 (en) * 2005-02-16 2009-07-28 Schering Corporation Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
US7615556B2 (en) 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
JP2010534669A (ja) 2007-07-24 2010-11-11 ブリストル−マイヤーズ スクイブ カンパニー ケモカイン受容体活性のモジュレーターとしての非環式誘導体
EP2173714B9 (en) 2007-07-24 2013-04-10 Bristol-Myers Squibb Company Piperidine derivatives as modulators of chemokine receptor activity
TWI433838B (zh) * 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
US9095585B2 (en) 2011-07-21 2015-08-04 Bristol-Myers Squibb Company Bioavailable compositions of amorphous piperidinyl compounds

Also Published As

Publication number Publication date
DK2323983T3 (da) 2014-03-31
IL209832A (en) 2014-09-30
EA201100088A1 (ru) 2011-06-30
JP2011526293A (ja) 2011-10-06
TWI433838B (zh) 2014-04-11
PL2323983T3 (pl) 2014-05-30
CA2729016A1 (en) 2009-12-30
IL209832A0 (en) 2011-02-28
EP2323983A1 (en) 2011-05-25
CN102076663B (zh) 2013-07-17
PT2323983E (pt) 2014-03-26
US8633226B2 (en) 2014-01-21
CL2010001566A1 (es) 2011-05-13
WO2009158452A1 (en) 2009-12-30
AU2009262219A1 (en) 2009-12-30
SI2323983T1 (sl) 2014-04-30
HK1154003A1 (en) 2012-04-13
TW201004927A (en) 2010-02-01
AU2009262219B2 (en) 2014-03-13
US8299098B2 (en) 2012-10-30
BRPI0914539A2 (pt) 2015-12-15
NZ589909A (en) 2012-04-27
KR20110023865A (ko) 2011-03-08
CY1114994T1 (el) 2016-12-14
CO6321247A2 (es) 2011-09-20
US20090326010A1 (en) 2009-12-31
US20130023564A1 (en) 2013-01-24
EP2323983B1 (en) 2014-01-01
ES2447740T3 (es) 2014-03-12
CN102076663A (zh) 2011-05-25
EA021224B1 (ru) 2015-05-29
PE20110103A1 (es) 2011-02-14
JP5357965B2 (ja) 2013-12-04
MX2010013664A (es) 2011-01-14

Similar Documents

Publication Publication Date Title
Boxer et al. A highly potent and selective caspase 1 inhibitor that utilizes a key 3‐cyanopropanoic acid moiety
US20070010523A1 (en) Azaindazole compounds and methods of use
MA28509B1 (fr) Compteur et systeme de cartouche d'analytes de liquides organiques pour la realisation de dosages par liaison specifiques
EP1579186A4 (en) IDENTIFYING KINASE INHIBITORS
TWI348102B (en) Architecture and method for managing the sharing of logical resources among separate partitions of a logically partitioned computer system
AU744444B2 (en) Identification of drugs using complementary combinatorial libraries
EP1874183A4 (en) SYSTEM AND METHOD FOR USING IMAGE GUIDANCE FOR ACCESS TO A COCHLEA OF A LIFE
ES2447740T3 (es) Derivado de piperidinilo como modulador de la actividad de los receptores de quimiocinas
WO1998019162A9 (en) Identification of drugs using complementary combinatorial libraries
Vistoli et al. In silico prediction of human carboxylesterase-1 (hCES1) metabolism combining docking analyses and MD simulations
CA2777032A1 (en) Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity
Wang et al. Rational design of small-sized peptidomimetic inhibitors disrupting protein–protein interaction
Hosseinzadeh et al. Rational Design, Synthesis, Docking Simulation, and ADMET Prediction of Novel Barbituric‐hydrazine‐phenoxy‐1, 2, 3‐triazole‐acetamide Derivatives as Potent Urease Inhibitors
WO2004053459A3 (en) Compounds and mehtods of use thereof for assaying lysophospholipase d activity
Mahindroo et al. Structural basis for the structure− activity relationships of peroxisome proliferator-activated receptor agonists
Hashimoto et al. Thalidomide as a multi-target drug and its application as a template for drug design
Sun et al. DCAF16‐Based Covalent Molecular Glues for Targeted Protein Degradation of Histone Deacetylases
AU2003296196A1 (en) Method and system for measuring the velocity of a vessel relative to the bottom using velocity measuring correlation sonar
Abu Khalaf et al. Pharmacophore modeling and molecular docking studies of acridines as potential DPP-IV inhibitors
Hill et al. Enantioselective Synthesis of Protected l-4-[Sulfonamido (difluoromethyl)] phenylalanine and l-4-[Sulfonamido (methyl)] phenylalanine and an Examination of Hexa-and Tripeptide Platforms for Evaluating pTyr Mimics for PTP1B Inhibition
Zeyen et al. Identification of HDAC10 Inhibitors that Modulate Autophagy-Related Proteins in Transformed Cells
Argade et al. Design, synthesis and biological evaluation of γ-lactam hydroxamate based TACE inhibitors
Abdelsalam et al. Dual FLT3/MAPK14 Proteolysis-Targeting Chimera (PROTAC) Induces Potent Acute Myeloid Leukemia Cell Death
Wu Discovery, development, and characterization of functional small molecules
Cesarini et al. A new breeding site of the Cape Verde Purple Heron Ardea (purpurea) bournei on Santiago, Cape Verde Islands